Cancer drugmakers gain after Roche discloses positive data from drug study

Arcus Biosciences

23/08/2023 12:01

** U.S.-listed shares of cancer drugmakers rise premarket
after Roche  ROG.S  reported positive data from a study of its
new immunotherapy for patients with lung cancer
    ** The study used new experimental class of drugs known as 
anti-TIGIT
    ** Rival drugmaker Merck & Co  MRK.N  up 1.2% at $108.5,
Gilead Sciences  GILD.O  rises ~1% to $77.1 premarket, as they
are also evaluating the class of drugs for various oncology and
immunology diseases
    ** Among other anti-TIGIT drug developers, iTeos
Therapeutics  ITOS.O  jumps 28.5% to $15.11, Arcus Biosciences
 RCUS.N  climbs 24.6% to $23.44, U.S. shares of Compugen
 CGEN.TA  up 2% at $1.04 in premarket trading   
    ** Roche said interim results regarding overall survival
were not mature at the time of the second interim analysis,
adding that it would continue the study until it had made a
final analysis of overall survival
    

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))